Ionis Pharmaceuticals (IONS) PT Lowered to $54 at Morgan Stanley
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Nasdaq futures slip on chip weakness; S&P 500 holds gains
- Massive market rotation raises question: Is the sell-AI trade here to stay?
- Goldman sees major AI and data center policy implications from ‘blue tsunami’
- Nvidia chips stockpile in Hong Kong awaits China import approval - report
- Goldman says this FX trade is the best hedge for the AI drawdown
Tweet
Share
E-mailGet Alerts IONS Hot Sheet
Price: $40.15 --0%
Rating Summary:
18 Buy, 10 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 20 | Down: 36 | New: 6
Rating Summary:
18 Buy, 10 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 20 | Down: 36 | New: 6
Join SI Premium – FREE
Morgan Stanley analyst David Lebowitz lowered the price target on Ionis Pharmaceuticals (NASDAQ: IONS) to $54.00 (from $56.00) while maintaining a Underweight rating.
You May Also Be Interested In
- Freedom Broker Downgrades MasterCard (MA) to Hold
- MercadoLibre (MELI) PT Lowered to $2,258 at StoneX
- Magnite (MGNI) PT Raised to $44 at StoneX
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
